<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Since the early 1970s, a dramatic change has occurred in the epidemiology of esophageal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> in both North America and Europe: the incidence of <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> of the lower esophagus and esophagogastric junction is increasing </plain></SENT>
<SENT sid="1" pm="."><plain>Several lifestyle factors are implicated in this change, including <z:hpo ids='HP_0002020'>gastroesophageal reflux disease</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Primary esophageal <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> are thought to arise from <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo>, an acquired condition in which the <z:mpath ids='MPATH_458'>normal</z:mpath> esophageal squamous epithelium is replaced by a specialized metaplastic columnar-cell-lined epithelium.Today, <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">gerd</z:e> is recognized as an important risk factor in <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Progression of <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> to invasive <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> is reflected histologically by the <z:mpath ids='MPATH_160'>metaplasia</z:mpath>-<z:mpath ids='MPATH_589'>dysplasia</z:mpath>-<z:mp ids='MP_0002038'>carcinoma</z:mp> sequence </plain></SENT>
<SENT sid="4" pm="."><plain>Although several molecular alterations associated with progression of <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> to invasive <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> have been identified, relatively few will ultimately have clinical application </plain></SENT>
<SENT sid="5" pm="."><plain>Currently, the histologic finding of high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> remains the most reliable predictor of progression to invasive esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>However other promising molecular biomarkers include <z:mp ids='MP_0004024'>aneuploidy</z:mp>; 17p loss of heterozygosity, which implicates the TP53 <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> suppressor gene; cyclin D1 protein overexpression; and p16 alterations </plain></SENT>
<SENT sid="7" pm="."><plain>It is anticipated that models incorporating combinations of objective scores of sociodemographic and lifestyle risk factors (that is, age, sex, body mass index), severity of <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">gerd</z:e>, endoscopic and histologic findings, and a panel of biomarkers will be developed to better identify patients with <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> at increased risk for malignant progression, leading to more rational endoscopic surveillance and screening programs </plain></SENT>
</text></document>